Article
STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
Neuro-oncology - 3 Oct 2022
Zhang Liang, Nesvick Cody L, Day Charlie A, Choi Jonghoon, Lu Victor M, Peterson Timothy, Power Erica A, Anderson Jacob B, Hamdan Feda H, Decker Paul A, Simons Renae, Welby John P, Siada Ruby, Ge Jizhi, Kaptzan Tatiana, Johnsen Steven A, Hinchcliffe Edward H, Daniels David J
Abstract excerpt
BACKGROUND: H3K27M-mutant diffuse midline glioma (DMG) is a lethal brain tumor that usually occurs in children. Despite advances in our understanding of its underlying biology, efficacious therapies are severely lacking. METHODS: We screened a library of drugs either FDA-approved or in clinical trial using a library of patient-derived H3K27M-mutant DMG cell lines with cell viability as the outcome. Results were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.